Cargando…

A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis

Clinical trials in patients with ulcerative colitis (UC) face the challenge of high and variable placebo response rates. The Mayo Clinical Score (MCS) is used widely as the primary endpoint in clinical trials to describe the clinical status of patients with UC. The MCS is comprised of four subscores...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawakatsu, Sonoko, Zhu, Rui, Zhang, Wenhui, Tang, Meina T., Lu, Tong, Quartino, Angelica L., Kågedal, Matts
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940756/ https://www.ncbi.nlm.nih.gov/pubmed/34657238 http://dx.doi.org/10.1007/s10928-021-09789-2

Ejemplares similares

A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score
por: Moein, Anita, et al.
Publicado: (2023)

Comparison of the Mayo Endoscopy Score and the Ulcerative Colitis Endoscopy Index of Severity and the Ulcerative Colitis Colonoscopy Index of Severity
por: Belvis Jiménez, María, et al.
Publicado: (2021)

Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program
por: Sandborn, William J., et al.
Publicado: (2022)

Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: A prospective study
por: Shah, Jimil, et al.
Publicado: (2019)

Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis
por: Goll, Rasmus, et al.
Publicado: (2019)

Development and validation of a deep learning-based approach to predict the Mayo endoscopic score of ulcerative colitis
por: Qi, Jing, et al.
Publicado: (2023)

Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis
por: Viscido, Angelo, et al.
Publicado: (2022)

Full, Partial, and Modified Permutations of the Mayo Score: Characterizing Clinical and Patient-Reported Outcomes in Ulcerative Colitis Patients
por: Naegeli, April N, et al.
Publicado: (2021)

How disease extent can be included in the endoscopic activity index of ulcerative colitis: the panMayo score, a promising scoring system
por: Bálint, Anita, et al.
Publicado: (2018)

Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis
por: Xie, Tingbin, et al.
Publicado: (2018)

Time-adjusted average Mayo endoscopic score predicts the risk of disease extent progression in distal ulcerative colitis patients
por: Wan, Jian, et al.
Publicado: (2022)

Analysis of Longitudinal‐Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models
por: Lu, Tong, et al.
Publicado: (2020)

Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
por: Moein, Anita, et al.
Publicado: (2022)

The Mayo Endoscopic Score Is a Novel Predictive Indicator for Malignant Transformation in Ulcerative Colitis: A Long-Term Follow-Up Multicenter Study
por: Xu, Weimin, et al.
Publicado: (2022)

Impact of the Concomitant Use of Immunomodulator and a Lower Week 8 Partial Mayo Score on the Persistence of Adalimumab in Refractory Ulcerative Colitis
por: Kumei, Shinsuke, et al.
Publicado: (2021)

Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
por: Kassir, Nastya, et al.
Publicado: (2022)

Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
por: Dubinsky, Marla C, et al.
Publicado: (2022)

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
por: Wang, Bei, et al.
Publicado: (2021)

Deep learning model for distinguishing Mayo endoscopic subscore 0 and 1 in patients with ulcerative colitis
por: Kim, Ji Eun, et al.
Publicado: (2023)

Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis
por: Lee, Sun-Ho, et al.
Publicado: (2017)

Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore
por: Lee, Scott D., et al.
Publicado: (2023)

A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics
por: Yu, Jiajie, et al.
Publicado: (2020)

Reliability of the Endoscopic Ultrasound Ulcerative Colitis (EUS-UC) score for assessment of inflammation in patients with ulcerative colitis
por: Yan, Brian M., et al.
Publicado: (2021)

Castellano-mayo, mayo-castellano
por: Collard, Howard
Publicado: (1962)

Correlation of Biomarkers with Endoscopic Score: Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in Patients with Ulcerative Colitis in Remission
por: Pop, Corina Silvia, et al.
Publicado: (2020)

Early-Phase Partial Mayo Score following Golimumab Treatment Is Associated with Endoscopic Improvement at 1 Year in Ulcerative Colitis: A post hoc Analysis of PURSUIT-J Randomized Controlled Trial
por: Nagano, Katsumasa, et al.
Publicado: (2022)

Glycosides as Potential Medicinal Components for Ulcerative Colitis: A Review
por: Niu, Yating, et al.
Publicado: (2023)

Comparing the clinical application values of the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with ulcerative colitis
por: Zhang, Xiao-Fei, et al.
Publicado: (2021)

The 2 + 1 paradigm: an efficient algorithm for central reading of Mayo endoscopic subscores in global multicenter phase 3 ulcerative colitis clinical trials
por: Ahmad, Harris A., et al.
Publicado: (2016)

Analysis of Factors Influencing Mayo Adhesive Probability Score in Partial Nephrectomy
por: Ji, Chaoyue, et al.
Publicado: (2017)

Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis
por: Kerur, Basavaraj, et al.
Publicado: (2017)

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis
por: Middha, Pooja, et al.
Publicado: (2023)

Collected Papers of the Mayo Clinic and the Mayo Foundation
Publicado: (1926)

Collected Papers of the Mayo Clinic and the Mayo Foundation
Publicado: (1927)

Sketch of the History of the Mayo Clinic and the Mayo Foundation. From the Division of Publications. Mayo Clinic
Publicado: (1928)

Real-life evaluation of histologic scores for Ulcerative Colitis in remission
por: Arkteg, Christian Børde, et al.
Publicado: (2021)

Su1185 IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS ASSESSMENT AND PROGNOSIS: CAN UCEIS, MAYO AND NANCY INDEX SCORING POINT THE WAY?
por: Cheung, Vincent T., et al.
Publicado: (2020)

The ulcerative colitis endoscopic index of severity score is superior to reflecting long-term prognosis in ulcerative colitis patients treated with vedolizumab
por: Yan, Jing, et al.
Publicado: (2023)

A54 DIETARY COMPONENTS ARE ASSOCIATED WITH FECAL CALPROTECTIN IN ULCERATIVE COLITIS
por: Chiu, E, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis
por: Wei, Xiaohui, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_34vvma8l66uur6qekkd8f6edhh